# The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Study · id `cardio:ct-nct04572724` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04572724](<https://clinicaltrials.gov/study/NCT04572724>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04572724

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04572724. Non-randomized; no masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04572724, source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)
- Started: 2020-07-06 (actual) (ClinicalTrials.gov record NCT04572724, source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)
- Primary completion: 2022-11 (anticipated) (ClinicalTrials.gov record NCT04572724, source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)
- Completion: 2023-06 (anticipated) (ClinicalTrials.gov record NCT04572724, source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04572724, source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04572724-2020-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
- Condition: Peritoneal Dialysis Complication
- Condition: Hemodialysis Complication
- Condition: Heart Failure
- Intervention (Drug): Sacubitril / Valsartan Oral Tablet
- Intervention (Drug): RAS Inhibitors
- Lead sponsor: Shenzhen Second People's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Shenzhen Second People's Hospital (`cardio:org-shenzhen-second-people-s-hospital`)

## Provenance

Content hash: fd96848f88cee677f99daeeab8585a9968b249c3eabafd214830eea91ba390cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
